Clinical Trial Search

Primary: Percentage of Participants Maintaining Average Hemoglobin Concentration Within +/-1 Gram Per Deciliter (g/dL) of Reference and Within the Target Range — 53.3 percentage…

Primary: Number of Serious Adverse Events (SAEs) — 13 number of SAEs

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 176; 70 Participants

Primary: Disease-free Survival — 656; 603 Participants — p=0.053

Primary: Time to Treatment Failure on or After Week 2 — 8.3; NA; 5.6; NA months — p=0.004

Primary: Percent Change in Number of Active Joints With Arthritis From Baseline to Week 12 — -11.6; -62.6 percent change — p==0.039

Primary: Percentage of Participants (Par) Withdrawn From the Study Due to "Poorly-controlled Asthma" During Period 2 — 4.9; 7.3; 8.1 Percentage of Participants

Primary: Number of Subjects Aged 18-49 Years Reporting Solicited Local Adverse Events (AEs). — 41; 32; 1; 0 Subjects

Primary: Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma — 3.8; 29.35 cmˆ3 — p=<0.05

Primary: Number of Patients With Serious Adverse Events — 55; 55; 50 Participants

Primary: Progression Free Survival(PFS) — 2.6; 1.8 month

Primary: Freedom From Target Lesion Revascularization (TLR) — 123; 43 # of participants free from TLR

Primary: Percentage of Participants Who Were Treatment Failures — 24.6; 44.8 percentage of treatment failures

Primary: Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE) — 25; 25; 22; 21 participants

Primary: Percentage of Participants With >=4 Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) for 4 Primary Strains and Composite Response (hSBA >=Lower Limit…